On May 1, the US Food and Drug Administration (FDA) announced that it is proposing to exclude semaglutide, tirzepatide, and liraglutide from the ...
If your medical practice or pharmacy compounds, prescribes, or dispenses semaglutide or tirzepatide, you may already be in the crosshairs of pharmaceutical giants Novo Nordisk and Eli Lilly.
Testing identified significant impurity formation when tirzepatide is compounded with B12 variants, suggesting chemical incompatibility that is not evaluated under FDA review pathways. Uncertainty ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results